Methods of immunosuppression for study of growth and lung colony formation by human tumor cells in mice.
Mice that are immune-suppressed by thymectomy and by sequential treatment with 1-beta-D-arabinofuranosylcytosine and whole body irradiation may be used as hosts for generation of human tumor xenografts. We have studied the effect of various additional methods of immune suppression on the formation of tumors after i.m. injection and on the formation of lung colonies after i.v. injection with the human MGH-U1 bladder cancer cell line. Success of transplantation was improved by treatment of immune-suppressed animals with either heterologous antilymphocyte serum or a monoclonal anti-Thy-1.2 antibody. Success of lung colony formation was also improved by antilymphocyte serum but not by monoclonal anti-Thy-1.2 antibody. Admixture of heavily irradiated cells (10(6)) to the viable inoculum of tumor cells in addition to antilymphocyte serum treatment improved the success of i.m. transplantation but not that of lung colony formation. Treatment with corticosteroids or treatment with carrageenan to suppress macrophage activity added toxicity and did not improve the success of xenografting. Immune suppression decreased the natural killer cell activity of normal mice and treatment with antiinterferon to further suppress natural killer cells may also enhance xenograft formation. Administration of cyclosporin A to normal mice allowed the growth of a single xenograft but was not a useful method for immunosuppression. The success of xenografting into immune-deprived mice was superior to that for two strains of nude mice maintained in our laboratory, and i.v. injection of tumor cells did not lead to lung colonies in these nude mice. Immune-deprived mice are a useful alternative to nude mice for the study of xenografts derived from human tumor cell lines and may allow the study of experimental lung metastases.
D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D002351:Carrageenan / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D003524:Cyclosporins / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D007165:Immunosuppression Therapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000556:secondary*; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000473:pathology*; D013934:Thymectomy; D014183:Transplantation, Heterologous; D014916:Whole-Body Irradiation
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D003561:Cytarabine; D004958:Estradiol; D003520:Cyclophosphamide; D002351:Carrageenan; D008775:Methylprednisolone